HCA Healthcare, Inc. (HCA)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for a business I can understand, run by capable people, at a sensible price. HCA is understandable: it owns hospitals and outpatient facilities, and scale matters in local markets. The numbers show steady progress. For FY2025, the period ended 2025-12-31, revenue was $75.6B, net income $6.8B, and diluted EPS $28.33, up from FY2024 revenue $70.6B, net income $5.8B, and EPS $22.00. That is real growth. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue rose to $19.1B from $18.3B in fiscal Q1 2025, while diluted EPS improved to $7.15 from $6.45. Free cash flow of $6.0B and a 5.9% FCF yield are attractive. FairStock's P/E of 15.45 at the 2026-10-13 close is not demanding for a stalwart, and ROCE of 12.29% indicates decent capital returns. The Piotroski F-Score of 8 out of 9 suggests improving financial strength. However, the Altman Z-Score of 1.26 and PEG ratio of 5.56 warn that growth may not justify the multiple, and the balance sheet deserves scrutiny. The dividend yield is small at 0.68%, so returns depend on earnings growth and buybacks, not income. HCA's local hospital networks and outpatient footprint give it some staying power, but healthcare reimbursement, labor costs, and regulation are persistent risks. At $460.75, the stock is reasonably priced, not a bargain-bin Graham cigar butt. I would want a margin of safety and evidence that profit growth can reaccelerate.

In plain English: HCA runs hospitals and many other care centers in the United States. The business looks steady and produces a lot of cash, with sales and profits growing over recent years. At $460.75, the stock looks neither clearly cheap nor clearly expensive compared with those numbers, though it carries some financial risk.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer